AstraZeneca announced that the Food and Drug Administration (FDA) has approved Xigduo XR (dapagliflozin and metformin HCl extended-release) for adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
Xigduo consists of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2), and metformin HCl extended-release, a biguanide. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Xigduo XR is the first once-daily tablet that combines an SGLT2 inhibitor and metformin HCl extended-release.
Xigduo XR will be available in 5mg/500mg, 5mg/1000mg, 10mg/500mg, and 10mg/1000mg strength tablets in various 30-, 60-, 90-, 400-, and 500-count bottles.
For more information call (800) 236-9933 or visit AstraZeneca.com.